Speaker illustration

Doctor Aoife Gowran

Cardiology Center Monzino IRCCS, Milan (Italy)

In 2014 Aoife moved from Dublin to Milan where she established the an induced pluripotent stem cells (iPSC) research program and iPSC Group in the Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino. The iPSC Group works together to create cutting-edge precision models of cardiomyopathy and also investigates the value of bio-engineered substrates and microfluidic platforms to benefit both the cell maturity and disease-model faithfulness. Recently, her group has received major funding from EU, national and private enterprise sources (European Research Area Network on Cardiovascular Diseases, Fondazione Telethon, Unione Italiana Lotta alla Distrofia Muscolare, Italian Ministry of Health, Umberto Veronesi Foundation, Fondazione IEO-CCM, Italfarmaco s.r.l.). She continues to collaborate with investigators in Italy and abroad.

The cannabinoid receptor type two is a therapeutic target for muscular dystrophy cardiomyopathy.

Event: Frontiers in CardioVascular Biology 2018

Topic: Stem Cells, Cell Cycle, Cell Senescence, Cell Death

Session: Basic Science - Cardiac Biology and Physiology

Thumbnail

The endocannabinoid system is a novel therapeutic target for muscular dystrophy cardiomyopathy.

Event: ESC CONGRESS 2017

Topic: Stem cells and cell therapy

Session: Best Posters in genomics to therapy

Thumbnail

The role of the endocannabinoid system in modelling muscular dystrophy cardiac disease with induced pluripotent stem cells.

Event: Frontiers in CardioVascular Biology 2016

Topic: Cell growth, differentiation and stem cells - Heart

Session: Cell growth, differentiation and stem cells - Heart

Thumbnail

This platform is supported by

logo Novo Nordisk